Neurologia Hi-Tech all’ American Academy of Neurology.
52° Congresso Annuale a San Diego, 2000

Renzo Bassi
Servizio di Neurofisiopatologia.
Ospedale Civile di Legnago (VR)
       

Il piu’ importante congresso mondiale di neurologia ha concluso la decade che negli USA e’ stata dedicata al cervello.
L’associazione principale dei neurologi americani si presenta piu’ che mai impegnata socialmente e politicamente a difendere e portare avanti gli interessi e le tematiche della disciplina.
E’ stata data enfasi alla pubblicazione di linee guida e ai principi della neurologia basata sulle prove di efficacia, stese da appositi comitati per conto dell’American Academy.
L’associazione stessa ha presentato le proprie molteplici sezioni che si interessano delle aree sottospecialistiche come la neurologia intervenzionale, la neurologia dell’emergenza e della terapia intensiva e quella per la patologia femminile.
Il congresso mostrava un importante risvolto tecnologico come da "Stato dell’Arte" dell’ Information Technology in campo specialistico.
Un centro di risorse tecnologiche ( e di comunicazione elettronica) molto frequentato presentava i piu’ avanzati prodotti informatici con 30 computer con monitor lcd a 20 pollici, abilitati alla rete internet e alla creazione di proprie presentazioni.
Nonostante il parco di audiovisivi digitali dell’ultima generazione, la maggior parte della relazioni erano pero’ basate sulle classiche diapositive.

Ben quattro sessioni erano dedicate a temi nell’ambito dell’ Information Technology:

  • Using Electronic media for Education and Scientific Writing : Why and How
  • Using Power Point to give effective laptop presentations
  • Course for effective Medical Journalism
  • Selecting a Computer System

L’esposizione delle ditte di biomedicali confermava il predominio assoluto del digitale e delle soluzioni basate su pc.
Sono stati infine presentati nuovi testi didattici elettronici di neurologia che saranno diffusi nella rete Internet. Dal sito dell’AAN (www.aan.com) e’ ora scaricabile una elegante presentazione in power point sulle concussioni cerebrali nello sport.

Gli iscritti al congresso erano 7654 di cui 436 italiani. La pattuglia nostrana, arrivata per lo piu’ col supporto di sponsor farmaceutici, era presente attivamente con un discreto numero di posters e alcune comunicazioni orali, ma assente nella mumerose sessioni didattiche. Su circa 1500 presentazioni, autori italiani ne avevano firmato poco piu’ di 100.
Analogamente agli ultimi anni, i lavori e i seminari dedicati alla neurofisiologia e alle malattie neuromuscolari costituiscono ancora una parte consistente.
In allegato gli echi del congresso che i megasiti medici ( Reuters health, Intelihealth, Docguide ) hanno deciso di riportare nei servizi di alerting, enfatizzando la farmacoterapia:

Botulinum Toxin A Injection Effective For Back Pain
SAN DIEGO (Reuters Health) - Paravertebral injection of botulinum toxin A in patients with chronic mechanical low back pain can reduce pain and improve functionality for a minimum of 2 months, according to study findings presented at the 52nd Annual Meeting of the American Academy of Neu rology.

Researchers Identify Brain's 'Moral Center'
SAN DIEGO, CA (Reuters Health) - The brain's moral center—the bit that sorts "right" from "wrong"--has been identified on brain magnetic resonance imaging, researchers reported here at the American Academy of Neurology's 52nd annual meeting.

IV Valproate Sodium Effective For Refractory Migraines
SAN DIEGO, CA (Reuters) - Repetitive intravenous administration of valproate sodium may be preferable to IV dihydroergotamine in treating intractable migraine headaches, according to findings presented at the 52nd annual meeting of the American Academy of Neurology.

Anticonvulsant Prevents Headache In Migraineurs Refractory To Other Treatments
SAN DIEGO, CA (Reuters Health) - New results reported at the 52nd annual meeting of the American Academy of Neurology document the efficacy of topiramate in migraine prophylaxis.

Promising Gene Therapy Could Rejuvenate Aging Brain Networks
SAN DIEGO (American Academy of Neurology) - Age-related deterioration in critical brain networks may be restored by gene therapy, according to a study in monkeys presented at the American Academy of Neurology's 52nd Annual Meeting in San Diego, CA, April 29 -- May 6, 2000. This finding lends support to a study just underway to treat Alzheimer's disease using a similar gene therapy approach, say the study's authors.

Galantamine Shows Potential Benefits In Alzheimer's Disease
SAN DIEGO (Reuters Health) - The investigational drug galantamineproduces cognitive and functional benefits that are maintained for at least 12 months in patients with Alzheimer's disease, according to results presented later at the 52nd Annual Meeting of the American Academy of Neurology.

> DG DISPATCH - AAN: Management of ALS not up to AAN guidelines
http://www.pslgroup.com/dg/1d0592.htm
Research shows current management of amyotrophic lateral sclerosis is not up to the established best management practices.

> DG DISPATCH - AAN: Donepezil showed to delay function decline in Alzheimer's
http://www.pslgroup.com/dg/1d0586.htm
Donepezil delays functional decline in patients with Alzheimer's disease, according to researchers.

> AAN: Concerta (methylphenidate HCl) ER improves attention, behaviour in ADD/ADHD
http://www.pslgroup.com/dg/1d057a.htm
Researchers have noted a significant improvement in attention and behaviour in children with ADD/ADHD treated with Concerta (methylphenidate HCl) extended-release tablets.

AAN: Addictive behavior cause linked to lower Parkinson's risk
http://www.pslgroup.com/dg/1d030e.htm

> DG DISPATCH - AAN: Initial treatment for Parkinson's with dopamine rather than levodopa can delay motor complications
http://www.pslgroup.com/dg/1cfce6.htm

> DG DISPATCH - AAN: Viagra (sildenafil) may reduce levodopa-induced dyskinesia in Parkinson's patients
http://www.pslgroup.com/dg/1cfcd2.htm

Investigational Agent Shows Promise For Treatment Of Diabetic Neuropathy
SAN DIEGO (Reuters) - Memantine, an N-methyl-D-aspartate (NMDA) receptor blocker, significantly decreases nighttime pain associated with diabetic peripheral neuropathy, according to study results released here at the 52nd Annual Meeting of the American Academy of Neurology.
http://ipn.intelihealth.com/IPN/ihtIPN?st=23883&t=7223&c=280220

Criteria For Treatment Of Secondary Progressive MS With Interferon-Beta-1b Clarified
SAN DIEGO, CA (Reuters Health) - Patients with secondary progressive multiple sclerosis who continue to experience relapses should be treated with interferon (IFN) beta-1b, researchers from the US and Europe said at a late-breaking news session here during the 52nd annual meeting of the American Academy of Neurology.
http://ipn.intelihealth.com/IPN/ihtIPN?st=23883&t=7223&c=279911 

> AAN: Patients With Peritumoral Brain Edema Improve With Xerecept (Human Corticotropin-Releasing Factor)
http://www.pslgroup.com/dg/1d126a.htm
Patients with peritumoral brain edema showed significant improvement in primary neurologic
evaluations when treated with Xerecept (human corticotropin-releasing factor).

> AAN: Axert (almotriptan malate) as effective as Imitrex (sumatriptan) with fewer side effects
http://www.pslgroup.com/dg/1d067e.htm

> DG DISPATCH - AAN: Stratified care more effective than stepped care for migraine
http://www.pslgroup.com/dg/1cf5b6.htm

 

Pubblicazione su "E-Neuro":  19 giugno 2000

Corrispondenza con l'Autore: renzobassi@indicemedico.it

www.seiemg.it

Prodotti per

Neurofisiologia